Oncology Pathways Engagement provides insights on the evolution of oncology pathways, supporting timely, effective engagement with each stakeholder type to optimize access for branded oncology drugs.
What are the current and projected implementation levels of oncology pathways by cancer type?
Which stakeholders have the greatest influence on oncology pathway development?
What are the key features of the trade-off analysis that oncologists use to choose between plan-, system-, and group-developed pathways?
Where do individual health plans and organized providers fall on the continuum of oncology pathway implementation, measurement, and adherence?
What are the best opportunities to increase brand inclusion in oncology pathways?
Use Oncology Pathways Engagement to:
- Assess current levels of oncology pathway implementation, measurement, and adherence
- Gain in-depth understanding of impact of oncology pathways and factors promoting their continued use by stakeholders
- Identify customer engagement strategies that effectively promote inclusion of brands in oncology pathways
-
Oncology Pathway Landscape April
- Health plan, organized provider, oncologist, and pathway vendor role and influence in oncology pathway development, participation, and adherence
- Assessment of oncologist pathway adoption at point of care, including rationales (e.g., financial incentives) for choosing plan, group, or system pathways
-
Health Plan Segmentation and Profiles May
- Framework identifying individual health plan placement on the continuum of pathway implementation, measurement, and adherence, with connection tree comprising key influencers in pathway development
- Profiles of 20 health plans, including current pathway implementation and key attributes by cancer type
-
Organized Provider Segmentation and Profiles June
- Framework identifying individual organized provider placement on the continuum of pathway implementation, measurement, and adherence
- Profiles of 80 organized providers (integrated health systems and community-based oncology practices), including current pathway implementation and key attributes by cancer type
-
Engaging with Oncology Pathway Vendors September
- Profiles of oncology pathway vendor organizations, including current offerings and level of treatment recommendation adoption by customers
- Identification of key influencers of pathway development and assessment of opportunities for biopharmaceutical company engagement with pathway vendors
-
Additional Service Offerings
- In-depth report and chart pack analyzing pathways landscape by specific cancer type
- In-depth report and chart pack analyzing benchmarking and best practices in pathway-specific engagement by biopharmaceutical companies
- Account training on customer engagement relating to oncology pathways